Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care At the EAU 2026 Congress, Photocure presented innovative trials focusing on personalized treatments for bladder cancer, enhancing patient outcomes through advanced methodologies.

Innovative Bladder Cancer Trials Presented at EAU 2026 Congress for Enhanced Patient Care #Norway #Oslo #Bladder_Cancer #Photocure #Hexvix

Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth Photocure ASA has announced strong financial results for Q3 2025, showcasing significant revenue growth and strategic partnerships aimed at enhancing bladder cancer detection.

Photocure ASA Reports Impressive Q3 2025 Results with Strong Revenue Growth #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook Photocure ASA highlights strong financial performance in Q3 2025, with increasing revenues and the advent of strategic partnerships for growth. Looking ahead, they anticipate sustained growth in bladder cancer diagnostics.

Photocure ASA Reports Impressive Q3 2025 Financial Results with Continued Growth Outlook #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales Photocure ASA has reported impressive growth for Q1 2025, with revenues of NOK 125.3 million and a focus on expanding bladder cancer treatments using innovative technologies.

Photocure ASA Reports Strong Growth in Q1 2025 with Boost in Bladder Cancer Product Sales #Norway #Oslo #Bladder_Cancer #Photocure #Hexvix

Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments Photocure ASA has announced a revenue increase for Hexvix®/Cysview® in Q1 2025. With strong performance in Europe and North America, growth looks promising for the year ahead.

Photocure ASA Reports Strong Financial Results for Q1 2025 with Continued Growth in Bladder Cancer Treatments #Norway #Oslo #Bladder_Cancer #Photocure_ASA #Hexvix

Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment At the EAU 2025 congress, Photocure ASA highlights significant advantages of Blue Light Cystoscopy in managing bladder cancer and reducing recurrence rates.

Exploring the Groundbreaking Benefits of Blue Light Cystoscopy in Bladder Cancer Treatment #Photocure_ASA #Blue_Light_Cystoscopy #Hexvix

Photocure ASA Reports Strong Growth for Q4 2024 Results Photocure ASA shares impressive fourth quarter results with record revenues and product growth for Hexvix and Cysview, projecting continued success for 2025.

Photocure ASA Reports Strong Growth for Q4 2024 Results #Norway #Oslo #Photocure_ASA #Hexvix #Cysview

Photocure ASA Reports Robust Financial Performance in Q4 2024 Photocure ASA showcases impressive revenue growth in Q4 2024, driven by rising sales of Hexvix®/Cysview®. The company anticipates continued momentum through 2025.

Photocure ASA Reports Robust Financial Performance in Q4 2024 #Norway #Oslo #Photocure_ASA #Hexvix #Cysview